Compare ARK Space & Defense Innovation ETF (ARKX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Cassava Sciences Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.43, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | FLNA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $4.64 |
52-Week Low | $25.46 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKX trades at $34.27, up 3.82% today, with a bullish technical signal from moving averages and ADX indicators, though RSI_6 suggests overbought conditions. The ETF focuses on space exploration and innovation, holding positions in companies like SpaceX and Rocket Lab, benefiting from strong sector tailwinds and recent SpaceX IPO momentum.
Outlook is positive due to growth in the space economy, but risks include high volatility and stretched valuations in key holdings. Investors should weigh exposure to speculative tech against potential regulatory and competitive pressures in the evolving market.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
